Schirrmacher V - Search Results

1

High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients.

Schmitz-Winnenthal FH, Volk C, Z'graggen K, Galindo L, Nummer D, Ziouta Y, Bucur M, Weitz J, Schirrmacher V, Büchler MW, Beckhove P. Schmitz-Winnenthal FH, et al. Among authors: schirrmacher v. Cancer Res. 2005 Nov 1;65(21):10079-87. doi: 10.1158/0008-5472.CAN-05-1098. Cancer Res. 2005. PMID: 16267034

2

Immunity and metastasis: in situ activation of protective T cells by virus modified cancer vaccines.

Schirrmacher V. Schirrmacher V. Cancer Surv. 1992;13:129-54. Cancer Surv. 1992. PMID: 1423321 Review.

3

An analysis of autologous T-cell anti-tumour responses in colon-carcinoma patients following active specific immunization (ASI).

Patel BT, Lutz MB, Schlag P, Schirrmacher V. Patel BT, et al. Among authors: schirrmacher v. Int J Cancer. 1992 Jul 30;51(6):878-85. doi: 10.1002/ijc.2910510608. Int J Cancer. 1992. PMID: 1639535 Clinical Trial.

4

Tumor-specific T-cell clones recognize different protein determinants of autologous human malignant melanoma cells.

Notter M, Schirrmacher V. Notter M, et al. Among authors: schirrmacher v. Int J Cancer. 1990 May 15;45(5):834-41. doi: 10.1002/ijc.2910450508. Int J Cancer. 1990. PMID: 2159436

5

Isolation of a human melanoma adapted Newcastle disease virus mutant with highly selective replication patterns.

Ahlert T, Schirrmacher V. Ahlert T, et al. Among authors: schirrmacher v. Cancer Res. 1990 Sep 15;50(18):5962-8. Cancer Res. 1990. PMID: 2203523

6

Postoperative active specific immunization in colorectal cancer patients with virus-modified autologous tumor-cell vaccine. First clinical results with tumor-cell vaccines modified with live but avirulent Newcastle disease virus.

Bohle W, Schlag P, Liebrich W, Hohenberger P, Manasterski M, Möller P, Schirrmacher V. Bohle W, et al. Among authors: schirrmacher v. Cancer. 1990 Oct 1;66(7):1517-23. doi: 10.1002/1097-0142(19901001)66:7<1517::aid-cncr2820660714>3.0.co;2-i. Cancer. 1990. PMID: 2208003

7

Recruitment and activation of tumor-specific immune T cells in situ: functional studies using a sponge matrix model.

Zangemeister U, Thiede K, Schirrmacher V. Zangemeister U, et al. Among authors: schirrmacher v. Int J Cancer. 1989 Feb 15;43(2):310-6. doi: 10.1002/ijc.2910430225. Int J Cancer. 1989. PMID: 2783923

8

Biotherapy of cancer. Perspectives of immunotherapy and gene therapy.

Schirrmacher V. Schirrmacher V. J Cancer Res Clin Oncol. 1995;121(8):443-51. doi: 10.1007/BF01218359. J Cancer Res Clin Oncol. 1995. PMID: 7642685 Review.

9

Persistence of dormant tumor cells in the bone marrow of tumor cell-vaccinated mice correlates with long-term immunological protection.

Khazaie K, Prifti S, Beckhove P, Griesbach A, Russell S, Collins M, Schirrmacher V. Khazaie K, et al. Among authors: schirrmacher v. Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7430-4. doi: 10.1073/pnas.91.16.7430. Proc Natl Acad Sci U S A. 1994. PMID: 8052600 Free PMC article.

10

A role for sialoadhesin-positive tissue macrophages in host resistance to lymphoma metastasis in vivo.

Umansky V, Beckhove P, Rocha M, Krüger A, Crocker PR, Schirrmacher V. Umansky V, et al. Among authors: schirrmacher v. Immunology. 1996 Feb;87(2):303-9. Immunology. 1996. PMID: 8698395 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

402 results

Search Page

Filters